Discover Oncology (Jun 2024)

Deciphering the role of zinc homeostasis in the tumor microenvironment and prognosis of prostate cancer

  • Tao Guo,
  • Jian Wang,
  • Xiangyu Meng,
  • Ye Wang,
  • Yihaoyun Lou,
  • Jianglei Ma,
  • Shuang Xu,
  • Xiangyu Ni,
  • Zongming Jia,
  • Lichen Jin,
  • Chengyu Wang,
  • Qingyang Chen,
  • Peng Li,
  • Yuhua Huang,
  • Shancheng Ren

DOI
https://doi.org/10.1007/s12672-024-01006-z
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 22

Abstract

Read online

Abstract Background Dysregulation of zinc homeostasis is widely recognized as a hallmark feature of prostate cancer (PCa) based on the compelling clinical and experimental evidence. Nevertheless, the implications of zinc dyshomeostasis in PCa remains largely unexplored. Methods In this research, the zinc homeostasis pattern subtype (ZHPS) was constructed according to the profile of zinc homeostasis genes. The identified subtypes were assessed for their immune functions, mutational landscapes, biological peculiarities and drug susceptibility. Subsequently, we developed the optimal signature, known as the zinc homeostasis-related risk score (ZHRRS), using the approach won out in multifariously machine learning algorithms. Eventually, clinical specimens, Bayesian network inference and single-cell sequencing were used to excavate the underlying mechanisms of MT1A in PCa. Results The zinc dyshomeostasis subgroup, ZHPS2, possessed a markedly worse prognosis than ZHPS1. Moreover, ZHPS2 demonstrated a more conspicuous genomic instability and better therapeutic responses to docetaxel and olaparib than ZHPS1. Compared with traditional clinicopathological characteristics and 35 published signatures, ZHRRS displayed a significantly improved accuracy in prognosis prediction. The diagnostic value of MT1A in PCa was substantiated through analysis of clinical samples. Additionally, we inferred and established the regulatory network of MT1A to elucidate its biological mechanisms. Conclusions The ZHPS classifier and ZHRRS model hold great potential as clinical applications for improving outcomes of PCa patients.

Keywords